Asia Pacific Newborn Screening Market, by Products Type (Hearing Screening Devices, Mass Spectrometer, Pulse Oximetry, and Assay Kits and Reagents), by Test Type (Phenylketonuria (PKU), Critical Congenital Heart Defect (CCHD), Hearing Screening, Sickle Cell Disease, Maple Syrup Urine Disease (MSUD), Thyroid Disorder, Biotinidase Deficiency (BTD), and Others), by End User (Hospitals, Maternity & Specialty Clinics, and Diagnostic Centers) and by Country (China, Japan, South Korea, ASEAN, India, Australia, and Rest of Asia Pacific) is estimated to be valued at US$ 308.9 Million in 2022 and is expected to exhibit a CAGR of 12.9% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Manufacturers are focusing on emerging countries such as China, India, for development of newborn screening devices, owing to relatively high birth rates. Furthermore, manufacturers are focusing on developing novel newborn screening methodology, which will be affordable, as the healthcare infrastructure is rapidly enhancing in Asia pacific countries and the regulatory scenario is also favorable for growth of the market. In November 2018, GE Healthcare collaborated with Beyond Zero Initiative to improve access to quality and affordable primary healthcare services in Kisumu County.
Asia Pacific Newborn Screening Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a negative impact on the Asia Pacific newborn screening market, owing to decrease in supply chain and healthcare services. For instance, in July 2020, according to data published by the National Center for Biotechnology Information, the COVID-19 pandemic has posed significant challenges for supply chains globally. Multiple national lockdowns continue to slow or even temporarily stop the flow of raw materials and finished goods, disrupting manufacturing as a result. The coronavirus disease 2019 (COVID-19) is an infectious disease. Since its first appearance in China in December 2019, it spread globally, resulting in an ongoing pandemic (Statista, 2020). The pandemic has provoked serious social and economic disruption globally, including strict social distancing, travel restrictions, and one of the largest global recessions. During the beginning of the global outbreak in March, supply chain (SC) management (SCM) has had major problems to cope with an unpredicted demand for certain products when simultaneous restrictions for travel and production have been enforced and is still struggling to recover from this (Mazareanu, 2020). The global COVID-19 pandemic has presented extraordinary disruption to healthcare services and exposed them to numerous challenges. Newborn screening (NBS) programs were also affected; however, scarce data exist on the impact of COVID-19 on NBS. Due the restriction imposed by the government of different countries
Asia Pacific Newborn Screening Market: Key Developments
In January 2022, in India, Bengaluru, the Ministry of Health implement the program to potentially improve and save the lives of around 2.5 lakh children in India every year. The Ministry of Health starts campaign for newborn screening program.
In November 2021, Masimo, medical device company, launched Dual SET Pulse Oximetry for Root, a highly versatile patient monitoring and connectivity hub. The first application of Dual SET Oximetry is a significant advancement to Masimo SET-guided critical congenital heart disease (CCHD) screening, with the CE marking and launch of the Masimo SET MOC-9 module and the addition of the Eve CCHD Newborn Screening Application for Root. Together, this combined solution enhances the automation of newborn screenings using Dual SET Oximetry: two simultaneous measurements of oxygen saturation (SpO2) at pre- and post-ductal sites by the intuitive Eve application, customized to align with a hospital’s CCHD screening protocol. CCHD affects approximately 2.5 to 3 newborns per 1,000 live births and requires intervention soon after birth to prevent significant morbidity or mortality; later detection in infants also increases the risk of brain damage.
Browse 32 Market Data Tables and 40 Figures spread through 193 Pages and in-depth TOC on “Asia Pacific Newborn Screening Market”- Forecast to 2030, Asia Pacific Newborn Screening Market, by Products Type (Hearing Screening Devices, Mass Spectrometer, Pulse Oximetry, and Assay Kits and Reagents), by Test Type (Phenylketonuria (PKU), Critical Congenital Heart Defect (CCHD), Hearing Screening, Sickle Cell Disease, Maple Syrup Urine Disease (MSUD), Thyroid Disorder, Biotinidase Deficiency (BTD), and Others), by End User (Hospitals, Maternity & Specialty Clinics, and Diagnostic Centers) and by Country (China, Japan, South Korea, ASEAN, India, Australia, and Rest of Asia Pacific)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/asia-pacific-newborn-screening-market-2546
Moreover, various national governments in the region are actively promoting the newborn hearing tests, which is expected to fuel demand for hearing screening in the near future. For instance, according to the International Journal of Preventative Health 2018 report, the Department of Prevention of Communication Disorders of All India Institute of Speech and Hearing (AIISH) located in the Southern India conducts infant screening for hearing disorder on regular basis in different hospitals using Behavioral Observational Audiometry, Otoacoustic Emissions (OAE) screening, and administering High Risk Register (HRR).
Key Takeaways of the Asia Pacific Newborn Screening Market:
- The Asia Pacific newborn screening market is expected to exhibit a CAGR of 12.9% during the forecast period due to the increasing government support to deploy efficient and cost-effective newborn screening devices.
- China holds the major share due to innovative and new initiatives by government for implementing various newborn screening programs. Currently Congenital Hypothyroidism (CH) and Phenylketonuria (PKU) and hearing loss are included as national wide screening program in China, which is also mandatory for all newborn. In addition to this, more than 150 Newborn Screening (NBS) labs in China offer screening program for Congenital Adrenal Hyperplasia (CAH) and Glucose-6-Phosphate Dehydrogenase Deficiency (G-6-PDD), and about 11 million babies had been screened for CAH and G6PD in 2017.
- India is expected to witness significant growth in the Asia Pacific newborn screening market, owing to high birth rate in this region. For instance, according to the World Health Organization (WHO) 2018, India’s total population was 1,324,171,000, which is second-largest in Asian countries after China. Newborn birth rate in India is around 34 births per second and 2,062 births per hour.
- Major players operating in the Asia Pacific newborn screening market include Medtronic plc, Agilent Technologies, Waters Technologies Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.
